UNSPSC 51422432: Hydrocortisone probutate

This classification denotes an anti-inflammatory agent with the molecular formula C28H40O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O6550D6K3A, chemically known as 11.beta.-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)pregn-4-ene-3,20-dione, but more generally known as hydrocortisone probutate, which bears US NIH Compound Identifier 636398. European Medicines Agency schedules hydrocortisone probutate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08065MIG.

UNSPSC 51422432 Hydrocortisone probutate is a Commodity code that, based on recent state and local procurement activity, covers pharmaceutical products and related health-system procurement rather than the specific active pharmaceutical ingredient its abstract name suggests. The recent opportunities tagged under this code reflect broader pharmacy and medication-supply procurement by state health agencies and county public health departments. Issuing bodies include county health systems (Seminole County, Florida) and state health commissions (Texas Health and Human Services Commission), indicating that the code captures activity across both local public health infrastructure and state-level pharmacy benefit and pharmaceutical distribution programs. The scope of work encompasses direct procurement of medications and drug-management systems, wholesale pharmacy services and direct-to-manufacturer contracting models, and related pharmacy benefit administration.

Recent activity concentrates in Texas and Florida. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, response due July 26, 2023; the contract term is two years with a one-year renewal option and includes E-Verify compliance and workers' compensation insurance requirements. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information from vendors with prior direct-contracting experience for self-insured employer and government health plans and capacity to implement value-based or outcomes-based pharmacy agreements; no formal response deadline or award value was specified in the RFI, which functions as preliminary market intelligence to inform subsequent formal procurement.